We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




First and Only AI Technology Identifies Suspected Strokes from Brain Scans

By MedImaging International staff writers
Posted on 02 Aug 2023
Print article
Image: The Full Brain Solution identifies MeVOs and LVOs in addition to aneurysms and hemorrhages (Photo courtesy of Aidoc)
Image: The Full Brain Solution identifies MeVOs and LVOs in addition to aneurysms and hemorrhages (Photo courtesy of Aidoc)

There is a significant prevalence of posterior large vessel occlusions (LVOs) and medium vessel occlusions (MeVOs). Each year in the United States, there are approximately 795,000 cases of strokes, with 87% being ischemic strokes. It is estimated that 25-40% of ischemic strokes are MeVOs and 24-46% of all ischemic strokes are LVOs, with 20-25% of LVOs being posterior. Now, an innovative solution significantly expands the anatomy assessed by artificial intelligence (AI) for potential strokes on computed tomography (CT) scans, facilitating the identification and care coordination of patients with MeVOs and both posterior and anterior LVOs.

Aidoc (Tel Aviv-Yafo, Israel) has rolled out its pioneering Full Brain Solution, marking a significant leap in medical technology in patient care. The Full Brain Solution is the first and sole AI technology capable of identifying suspected posterior and anterior LVOs and MeVOs on CT scans. The inclusion of posterior LVO and MeVO allows roughly double the number of patients to quickly receive life-saving therapy with AI-powered care coordination. In addition to acute ischemic stroke, the Full Brain Solution utilizes diverse AI technologies, including image-based identification and natural language processing, to identify and manage care for patients suffering from intracerebral hemorrhage, subdural hemorrhage, and brain aneurysms. This makes it the most comprehensive neurovascular AI solution.

The Full Brain Solution is deployed through Aidoc's proprietary operating system, aiOS, which allows organizations to consistently roll out AI solutions in large volumes and overcome hurdles related to legacy IT systems and separate physician workflows. The aiOS smoothly integrates with current IT infrastructure, facilitating the necessary scale to realize the full potential of AI in healthcare. It is also the only platform integrated into electronic health records (EHR). AI has proven highly successful in improving workflow for patients with anterior LVOs, reducing the time to treatment by nearly half. With Aidoc's Full Brain Solution, these advancements can extend to a substantially larger patient population, leading to improved care and ultimately, better patient outcomes.

"AI continues to drive significant gains and contributions in addressing the challenges health systems are facing," said Elad Walach, CEO, Aidoc. "Our groundbreaking Full Brain Solution is propelling AI into new and needed territories and proving impact to facilities by cutting the time to treatment nearly in half for twice as many patients. Our vision is to continue pushing boundaries, transforming the lives of a significantly larger patient population, elevating the standard of care, and driving remarkable improvements in patient outcomes."

Related Links:
Aidoc 

40/80-Slice CT System
uCT 528
New
Ultrasound-Guided Biopsy & Visualization Tools
Endoscopic Ultrasound (EUS) Guided Devices
Silver Member
X-Ray QA Meter
T3 AD Pro
Computed Tomography System
Aquilion ONE / INSIGHT Edition

Print article

Channels

MRI

view channel
Image: An AI tool has shown tremendous promise for predicting relapse of pediatric brain cancer (Photo courtesy of 123RF)

AI Tool Predicts Relapse of Pediatric Brain Cancer from Brain MRI Scans

Many pediatric gliomas are treatable with surgery alone, but relapses can be catastrophic. Predicting which patients are at risk for recurrence remains challenging, leading to frequent follow-ups with... Read more

Nuclear Medicine

view channel
Image: In vivo imaging of U-87 MG xenograft model with varying mass doses of 89Zr-labeled KLG-3 or isotype control (Photo courtesy of L Gajecki et al.; doi.org/10.2967/jnumed.124.268762)

Novel Radiolabeled Antibody Improves Diagnosis and Treatment of Solid Tumors

Interleukin-13 receptor α-2 (IL13Rα2) is a cell surface receptor commonly found in solid tumors such as glioblastoma, melanoma, and breast cancer. It is minimally expressed in normal tissues, making it... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.